Actively Recruiting
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
Led by IRCCS San Raffaele · Updated on 2024-02-20
30
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
CONDITIONS
Official Title
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6518 years
- Signed written informed consent
- Diagnosed with relapsing remitting multiple sclerosis (RRMS) according to the 2017 McDonald Criteria
- High clinical and MRI inflammatory disease activity (at least 2 clinical relapses, or 1 relapse with gadolinium-enhancing or new T2 MRI lesions in the past 12 months)
- Referred for treatment with aHSCT, alemtuzumab, or ocrelizumab/ofatumumab following Italian regulatory and European guidelines
You will not qualify if you...
- Diagnosed with primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) according to the 2017 McDonald Criteria
- Known allergies or intolerances to the active substances or excipients in the disease-modifying therapies
- Contraindications to the treatments according to product information
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele
Milan, Italy, 20132
Actively Recruiting
Research Team
A
Angela Genchi
CONTACT
L
Lucia Moiola
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here